Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis
The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS. Participants will receive outpatient TMS treatment over the course of 5-6 weeks. Participants will complete validated questionnaires and exams before, during, and after treatment.
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Multiple sclerosis (MS) is a chronic, immune-mediated disease of the central nervous system. Depression, or major depressive disorder, is highly prevalent in people with MS and often has a serious impact on quality of life. MDD can be difficult to treat with medications in MS. Transcranial magnetic stimulation (TMS) is a safe and approved treatment for treatment-resistant depression in the general population. However, little is known about the use of TMS for MDD in people with MS. This pilot study will evaluate the safety, feasibility, and preliminary efficacy of TMS for MDD in MS. Participants will receive outpatient neuronavigated-TMS for MDD. Various measures of MS and MDD symptoms will be monitored over the course of treatment. Clinical brain imaging will also be compared before and after TMS.
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University of Utah Health
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adults diagnosed with MDD and MS who are eligible for TMS
Description
Inclusion Criteria:
- Established diagnosis of multiple sclerosis (any subtype) by 2017 McDonald criteria
- Established diagnosis of major depressive disorder (MDD) by DSM-5 criteria
- Eligible for transcranial magnetic stimulation (rTMS) for depression
Exclusion Criteria:
- MS relapse and/or steroid use within 3 months
- Active suicidal ideation
- History of seizure/epilepsy, brain tumor, or stroke
- History of bipolar disorder or psychosis
- Currently or planning to become pregnant
Study Plan
How is the study designed?
Design Details
- Observational Models: CASE_ONLY
- Time Perspectives: PROSPECTIVE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Feasibility of TMS treatment for MDD, per participant retention rates.
Time Frame: 10 weeks
|
10 weeks
|
|
Safety and tolerability, to be evaluated by side effects and adverse events over the course of treatment.
Time Frame: 10 weeks
|
10 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Depression response rates (50% reduction in symptoms) will be measured using MADRS scores before and after treatment.
Time Frame: 10 weeks
|
10 weeks
|
|
Depression remission rates will be measured using MADRS scores before and after treatment.
Time Frame: 10 weeks
|
10 weeks
|
|
MS lesion burden on MRI will be compared before and after treatment to determine impact of TMS on white matter disease burden.
Time Frame: 1 year
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Mental Disorders
- Autoimmune Diseases
- Immune System Diseases
- Behavioral Symptoms
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Mood Disorders
- Depressive Disorder
- Behavior
- Multiple Sclerosis
- Depression
- Depressive Disorder, Major
- Depressive Disorder, Treatment-Resistant
Other Study ID Numbers
Other Study ID Numbers
- 00164631
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.